Can an extra drug flush out hidden HIV? new study seeks answers
NCT ID NCT06819176
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 4 times
Summary
This study tests whether adding the drug lenacapavir to standard HIV treatment can reduce the hidden HIV reservoirs that remain in the body. About 50 adults with well-controlled HIV will either continue their usual therapy or receive lenacapavir injections plus pills. Researchers will measure changes in HIV DNA levels over two years to see if this approach can help control the virus more effectively.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Walking groups could shield HIV-Positive latino men from heart disease
- Friends helping friends: a novel social-network strategy to boost HIV prevention
- Decade-Long study aims to unlock liver disease risks in HIV-Hepatitis b patients
- Could HIV and age weaken vaccine protection? study investigates
- Massive HIV database could unlock secrets of Long-Term health
- Can couples counseling curb HIV? new study tests dyadic approach in south africa